Investigators at Memorial Sloan Kettering Cancer Center have changed the rules of the clinical trial game in the first of what they say will be a new wave of studies that examine a drug's potential based on a broad patient population who share the same genetic mutation rather than cancer type.
Investigators at the Salk Institute have blazed a new trail branching out from the closely studied mGluR5 pathway in the brain, and they say it could ultimately lead to new therapies to treat neurodevelopmental disorders like autism and schizophrenia. Read more >>
A global team of scientists working with Johns Hopkins' Jordan Green has developed a new nonviral gene therapy for brain cancer, successfully testing it in the lab in cell lines as well as rat models for the disease. Read more >>
POPULAR COMMENT THREADS
Following up on some promising rodent studies, a team of investigators at UC San Francisco has helped substantiate that elevated levels of two proteins are linked with healthier hearts--an insight that will likely inspire more work into new cardiology therapies.
A team of scientists at UC Berkeley have developed a technique that utilizes the protective effects of brown fat--which may potentially lead to a new approach to manage obesity, diabetes and other metabolic disorders.
A team at The Scripps Research Institute (TSRI) have characterized a novel set of genes that are "switched on" during drug resistance of the important human pathogen—Staphylococcus aureus.
Tiny gold nanorods have been the subject of a number of preclinical studies. Now a team at the University of Kyoto in Japan says they coated the ultrathin rods with a fat-transporting protein and found that it could be a very effective treatment for pain.
Two researchers at the University of Houston say that recent work highlights the promise of liver X receptors, or LXRs, as a target for hard-to-treat cases of pancreatic cancer.
A group of specialists drawn from Brigham and Women's Hospital, Mass General and MIT have come up with a new delivery technology that they believe could make a radical difference for patients suffering from inflammatory bowel disease.
From Our Sister Sites
Shares of Patterson Companies were down more than 7% to $45.53 on Thursday morning, after the distributor announced disappointing results for its fiscal first quarter. The company reported sales of $1.1 billion and earnings of $46.9 million, or $0.47 a share. Even though earnings were up more than 17% year-over-year, analysts had been expecting EPS of $0.54 on sales of $1.8 billion.
Sterilization specialist Sterigenics International is investing $10 million to add a new gamma cell to its Gurnee, IL, facility.